Solu-Cortef

DRUG6 trials

Sponsors

Amsterdam UMC Stichting, Copenhagen University Hospital, Crinetics Pharmaceuticals Inc., Haukeland University Hospital, Beni-Suef University

Conditions

Addison DiseaseAdrenal Hyperplasia CongenitalOral Pyogenic GranulomaPancreatic conditions requiring pancreaticoduodenectomySevere acute infectionType 1 Diabetessuch as pancreatic head carcinoma or intraductal papillary mucinous neoplasms (IPMN).• ACTH-Dependent Cushing’s Syndrome. • Pituitary-dependent Cushing´s syndrome.

Phase 1

Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal Hyperplasia

CompletedNCT02096510

Haukeland University HospitalAddison Disease, Adrenal Hyperplasia Congenital

Start: 2014-03-27End: 2017-12-31Updated: 2024-06-07

Phase 2

Continuous Subcutaneous Hydrocortisone Infusion In Addison's Disease and Type 1 Diabetes

TerminatedNCT01840189

Haukeland University HospitalAddison Disease, Type 1 Diabetes

Start: 2013-04-24End: 2016-12-31Updated: 2024-03-01

Corticosteroid Intralesional Injection as an Alternative Treatment in Oral Pyogenic Granuloma in the Esthetic Zone.

Beni-Suef UniversityOral Pyogenic Granuloma

Start: 2022-05-01End: 2022-11-29Target: 30Updated: 2022-09-14

A Multicenter, Phase 2/3, Dose Range Finding Study to Evaluate the Efficacy and Safety of Atumelnant in Adults with ACTH-Dependent Cushing’s Syndrome (ADCS) Including an Open-Label Extension for Long-Term Assessment. (EQUILIBRIUM-ADCS)

Not yet recruitingCTIS2025-522648-42-01

Crinetics Pharmaceuticals Inc.• ACTH-Dependent Cushing’s Syndrome. • Pituitary-dependent Cushing´s syndrome.

Target: 25Updated: 2026-09-29

Phase 4

Preventing postoperative complications in patients undergoing high-risk pancreatoduodenectomy with a bundle approach including hydrocortisone, ocreotide, and teres ligament patch (PANENCA): an international randomized controlled multicenter trial

RecruitingCTIS2024-519667-18-00

Amsterdam UMC StichtingPancreatic conditions requiring pancreaticoduodenectomy, such as pancreatic head carcinoma or intraductal papillary mucinous neoplasms (IPMN).

Start: 2025-08-21Target: 400Updated: 2025-10-29

Individualized Multiplex Pathophysiological Treatment of Severe Acute Infections (IMPACT)

WithdrawnCTIS2025-522215-42-00

Copenhagen University HospitalSevere acute infection

Target: 300Updated: 2025-12-08